Heart with Leaves and Berries, symbolizing LopiGLIK's natural composition.

LopiGLIK®: A Natural Way to Lower Cholesterol and Protect Your Heart?

Avery Sinclair in Health & Wellness July 2025 • 3 min read.

"Discover how this novel nutraceutical could be a cost-effective solution for managing cardiovascular disease risk factors."

Cardiovascular disease (CVD) remains a leading cause of death worldwide, placing a significant burden on healthcare systems and economies. In Europe alone, CVD costs an estimated €210 billion annually. High levels of low-density lipoprotein cholesterol (LDL-C), often called 'bad' cholesterol, are a major risk factor for CVD.

For years, medications have been the primary approach to lowering cholesterol. However, many individuals are exploring alternative and complementary strategies, including nutraceuticals – dietary supplements with potential health benefits. These natural compounds offer a potentially gentler approach to managing cholesterol and supporting heart health.

A recent clinical trial investigated the effectiveness and cost of a novel nutraceutical called LopiGLIK® (LOPI) in lowering LDL-C and reducing CVD risk. This article breaks down the study's findings, exploring whether LOPI could be a valuable tool in the fight against heart disease.

LopiGLIK®: How Does It Stack Up?

Heart with Leaves and Berries, symbolizing LopiGLIK's natural composition.

The study, a single-blind, multicenter, randomized controlled trial, involved 573 adult patients with mild hypercholesterolemia (high cholesterol). Participants were divided into two groups: one receiving LopiGLIK® (LOPI) and the other receiving Armolipid Plus® (AP), a widely available cholesterol-lowering supplement, as a control.

Over 16 weeks, researchers tracked several key outcomes, including:

Primary Outcome: The percentage of patients achieving LDL-C levels below 130 mg/dL.
Secondary Outcomes: Reductions in HbA1c (a measure of long-term blood sugar control), survival analysis, and the hazard ratio (HR) associated with specific reductions in LDL-C and HbA1c. The study also assessed the cost per unit and per cure for each treatment.

So, what did the study reveal? Let's dive into the key findings.

The Takeaway: Is LopiGLIK® Right for You?

The study suggests that LopiGLIK® may be a more effective and less expensive option than Armolipid Plus® for lowering LDL-C and reducing CVD risk. However, it's essential to remember that this is just one study, and more research is always valuable. Before making any changes to your healthcare plan, always talk to your doctor or a qualified healthcare professional. They can assess your individual risk factors and help you determine the best course of action for your specific needs.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.2147/ceor.s172838, Alternate LINK

Title: A Single Blind, Multicenter, Randomized Controlled Trial To Evaluate The Effectiveness And Cost Of A Novel Nutraceutical (Lopiglik≪Sup≫&Amp;Reg;≪/Sup≫) Lowering Cardiovascular Disease Risk

Subject: Health Policy

Journal: ClinicoEconomics and Outcomes Research

Publisher: Informa UK Limited

Authors: Andrea Manfrin, Valentina Trimarco, Maria Virginia Manzi, Francesco Rozza, Raffaele Izzo

Published: 2018-10-01

Everything You Need To Know

What is LopiGLIK® and how might it help with heart health?

LopiGLIK® is being investigated as a nutraceutical – a dietary supplement – that may help lower LDL-C ('bad' cholesterol) and reduce the risk of cardiovascular disease (CVD). Clinical trials, like the one mentioned, are conducted to evaluate its effectiveness and cost compared to existing treatments like Armolipid Plus®.

What key health markers were monitored in the LopiGLIK® clinical trial?

The primary goal in the clinical trial was to determine the percentage of patients who could achieve LDL-C levels below 130 mg/dL using LopiGLIK®. Secondary outcomes included reductions in HbA1c (a measure of long-term blood sugar control), survival analysis, and cost-effectiveness compared to Armolipid Plus®. These factors help to assess LopiGLIK®'s overall impact on heart health and economic viability.

How was LopiGLIK® tested against other cholesterol-lowering treatments in the study?

The study compared LopiGLIK® to Armolipid Plus®, a widely available cholesterol-lowering supplement. Researchers tracked outcomes such as LDL-C levels and HbA1c over 16 weeks. The results indicated whether LopiGLIK® was more or less effective and/or costly than Armolipid Plus® in managing cholesterol and related risk factors. LopiGLIK® showed a greater impact at a lower cost in lowering LDL-C.

Why is lowering LDL-C important, and how does LopiGLIK® potentially fit into managing overall cardiovascular risk?

High LDL-C is a significant risk factor for cardiovascular disease (CVD). By exploring options like LopiGLIK® to manage cholesterol levels, individuals may reduce their risk of developing CVD. However, it's crucial to consider that managing CVD risk involves more than just cholesterol levels. It includes lifestyle modifications, blood sugar management (as indicated by HbA1c), and other factors. A holistic approach, guided by a healthcare professional, is always the best strategy.

What does the term 'single-blind, multicenter, randomized controlled trial' mean in the context of the LopiGLIK® study?

A single-blind, multicenter, randomized controlled trial, like the one described, is designed to minimize bias and provide reliable evidence. 'Single-blind' means that participants don't know which treatment they are receiving (LopiGLIK® or Armolipid Plus®), but the researchers do. 'Multicenter' indicates that the study was conducted at multiple locations, increasing the generalizability of the results. 'Randomized controlled trial' means that participants were randomly assigned to different treatment groups, helping to ensure that any observed differences are due to the treatments themselves and not other factors.